Clinical observation of different doses of rituximab for the treatment of severe pemphigus: A single-center prospective cohort study
Authors:
- 30 June 2022
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (2) , 500-502
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Diagnosis and management of pemphigus: Recommendations of an international panel of expertsJournal of the American Academy of Dermatology, 2020
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017
- Grading criteria for disease severity by pemphigus disease area indexThe Journal of Dermatology, 2014
- Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded studyBritish Journal of Dermatology, 2014
- Low-dose rituximab is effective in pemphigusBritish Journal of Dermatology, 2011